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Mutations in KIF11 Cause Autosomal-Dominant
Microcephaly Variably Associated with Congenital
Lymphedema and Chorioretinopathy
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Andreas van Impel,6 Anthony T. Moore,7 Bart L. Loeys,8 Arash Ghalamkarpour,3
Alexandros Onoufriadis,2 Ines Martinez-Corral,9 Sophie Devery,10 Jules G. Leroy,11 Lut van Laer,8
Amihood Singer,12 Martin G. Bialer,13 Meriel McEntagart,14 Oliver Quarrell,15 Glen Brice,14
Richard C. Trembath,2 Stefan Schulte-Merker,6 Taija Makinen,9 Miikka Vikkula,3,16 Peter S. Mortimer,17
Sahar Mansour,14 and Steve Jeffery1,*
We have identified KIF11 mutations in individuals with syndromic autosomal-dominant microcephaly associated with lymphedema
and/or chorioretinopathy. Initial whole-exome sequencing revealed heterozygous KIF11mutations in three individuals with a combina-
tion of microcephaly and lymphedema from a microcephaly-lymphedema-chorioretinal-dysplasia cohort. Subsequent Sanger
sequencing of KIF11 in a further 15 unrelatedmicrocephalic probands with lymphedema and/or chorioretinopathy identified additional
heterozygousmutations in 12 of them. KIF11 encodes EG5, a homotetramer kinesinmotor. The variety ofmutations we have found (two
nonsense, two splice site, four missense, and six indels causing frameshifts) are all predicted to have an impact on protein function. EG5
has previously been shown to play a role in spindle assembly and function, and these findings highlight the critical role of proteins
necessary for spindle formation in CNS development. Moreover, identification of KIF11 mutations in patients with chorioretinopathy
and lymphedema suggests that EG5 is involved in the development and maintenance of retinal and lymphatic structures.There is substantial phenotypic overlap between MLCRD
(microcephaly, primary lymphedema, and chorioretinal
dysplasia) syndrome (MIM 152950) and CDMMR (chorior-
etinal dysplasia, microcephaly, and mental retardation)
syndrome (MIM 156590).1 Both have been observed to
segregate with autosomal-dominant inheritance and
present with an overlapping, yet variable, spectrum of
CNS and ocular developmental anomalies.2,3 Micro-
cephaly, ranging frommild to severe, is the critical compo-
nent of both syndromes and is often associated with mild
to moderate developmental delay and a characteristic
facial phenotype4 (Figures 1A and 1B). Chorioretinopathy
constitutes the most common eye abnormality (Fig-
ure 1C). However, retinal folds, microphthalmia, and
myopic and hypermetropic astigmatism have also been re-
ported, and some individuals have no overt ocular pheno-
type.5 The presence of lymphedema has historically been
seen as the critical differentiating feature between the
two syndromes. The lymphedema in MLCRD is congenital
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isotope (technetium 99) uptake from the webspaces
between the toes (Figure 1E). We have identified causative
variants for this complex disease, and the fact that we
show that KIF11 mutations can cause both MLCRD and
CDMMR suggests that together, these syndromes should
be considered as a single entity that has variable clinical
features but a unified molecular basis.
Whole-exome sequencing has proved to be a successful
approach to identifying causative mutations in primary
lymphoedema.6–8 We therefore sought to establish the
molecular genetic basis of MLCRD by whole-exome
sequencing the DNA of five unrelated probands (individ-
uals MLCRD01:II-2, MLCRD02:II-2, MLCRD03:III-2,
MLCRD04:I-1, and MLCRD05:I-1 in Table 1 and Table S1,
available online) with microcephaly and lymphedema.
Subjects for this study were recruited from genetic, lym-
phovascular, and ophthalmic clinics in Europe. Informed
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Figure 1. Clinical Features of KIF11 Mutation-Positive Patients with MLCRD and CDMMR
(A) Facial features of individuals diagnosed with MLCRD.
(B) Facial features of individuals diagnosed with CDMMR. The faces in (A) and (B) are characteristic of the syndrome and have upslanting
palpebral fissures, a broad nose with a rounded tip, a long philtrum with a thin upper lip, a prominent chin, and prominent ears.
(C) A composite color photograph of the left fundus in patient CDMMR05 II-1 shows focal areas of peripheral chorioretinal atrophy.
(D) Bilateral, congenital lower-limb primary lymphedema in subjects with MLCRD involves the dorsa of the feet, which show pitting
edema, deep interphalangeal creases, small dysplastic nails, and wide-caliber veins.
(E) Comparison of lower-limb lymphoscintigraphy (imaging taken 2 hr after injection of radioactive isotope [technetium 99] into the
webspaces between the toes) in patient MLCRD01 II-2 and an unaffected control. The patient’s lymphoscintigraphy shows no signifi-
cant main-tract filling and therefore suggests initial lymphatic-vessel dysfunction.examination. Ethical approval for this study was obtained
from the South West London Research Ethics Committee
(REC Ref: 05/Q0803/257).
Whole-exome capture was performed by in-solution
hybridization, followed by massively parallel sequencing
with the SureSelect All Exon CCDS (Consensus Coding
Sequences) Target Enrichment System (Agilent)9 and
sequencing on a Genome AnalyserIIx (Illumina) with
76 bp paired-end reads. Sequence reads were aligned to
the reference genome (hg18) with Novoalign (Novocraft
Technologies SdnBhd). Duplicate reads, resulting from
PCR clonality or optical duplicates, and reads mapping to
multiple locations were excluded from downstream anal-
ysis. Depth and breadth of sequence coverage were calcu-
lated with custom scripts and the BedTools package.10
More than 5.1 Gb of sequence was generated for each
subject, such that >75% of the coding bases of the
CCDS-defined exome were represented by at least 20 reads
(Table S2). Single-nucleotide substitutions and small indel
variants were identified and quality filtered within the
SamTools software package11 and in-house software tools
(Table S3).12 Variants were annotated with respect to genes
and transcripts with the Annovar tool.13 We filtered vari-
ants for novelty by comparing them to dbSNP132 and
1000 Genomes SNP calls (December 2010) and to variants
identified in 250 control exomes (primarily of European
origin), which we sequenced and analyzed by the same
method described above.
Analysis of the exome-variant profiles was performed
under a model of a rare autosomal-dominant disorder;
this model required at least one previously unobserved,
heterozygous nonsynonymous or splice-site substitutionThe Americaor an insertion or deletion in the same gene in all five indi-
viduals. This analysis failed to identify a single genematch-
ing these criteria (Table S4). Further evaluation of the data
with an expectation of genetic heterogeneity among these
five cases revealed KIF11 to be the only gene that harbored
previously unobserved variants in three of the five individ-
uals (Table S4). All three allelic mutations (a nonsense
variant [p.Arg387*], a single-nucleotidedeletion [p.Ile1006-
Leufs*62], and a dinucleotide deletion [p.Leu347Glufs*8])
are predicted to cause changes to the KIF11 protein product
(Table 1). All were confirmed by Sanger sequencing (primer
sequences are listed in Table S5). Sequencing in the two
subjects, in whom exome sequencing did not reveal novel
KIF11 variants, confirmed the wild-type coding sequence.
Our findings indicate that heterozygous mutations of
KIF11 underlie a significant proportion of MLCRD, and
we therefore assessed KIF11 for mutations in other MLCRD
cases by Sanger sequencing in probands from nine addi-
tional families, including a large multigenerational pedi-
gree (MLCRD11, Figure S1). In these probands, sequencing
revealed sevenmore independent heterozygous KIF11 vari-
ants: three frameshift insertions and deletions, two
missense substitutions, an acceptor splice-site substitution,
and a donor splice-site change that was observed in the
proband from the multigenerational pedigree (Table 1).
Each of the ten identified KIF11 alleles was assessed in all
available relatives; two were shown to have arisen de
novo, and eight demonstrated cosegregation with micro-
cephaly, variable in its severity, and with a spectrum of
eye and lymphatic abnormalities (Table1). In total,we iden-
tified KIF11 mutations in 10 of the 14 MLCRD-affected
families examined.n Journal of Human Genetics 90, 356–362, February 10, 2012 357
Table 1. Clinical and Genetic Findings in KIF11-Mutation-Positive Patients
Pedigree Individual Gender
Head
Circumferenceb Lymphedema Eye Abnormalities
Additional Clinical
Features Nucleotide Variant Exon Protein Alteration
MLCRD01 I-1 male 3.0 minimal edema none mild LD c.1159C>T 10 p.Arg387*
II-2a female 7.2 congenital, bilateral,
and lower limb
none mild LD and
dysmorphic features
c.1159C>T 10 p.Arg387*
MLCRD02 I-1 female 1.6 none diabetic retinopathy mild LD c.3016delA 21 p.Ile1006Leufs*62
II-2a female 4.0 congenital, bilateral,
and lower limb
none mild dysmorphic
features
c.3016delA 21 p.Ile1006Leufs*62
MLCRD03 II-1 male 2.0 none none mild LD c.1039_1040delCT 9 p.Leu347Glufs*8
III-2a female 7.5 congenital, bilateral,
and lower limb plus
pleural effusions
hypermetropic
astigmatism and
chorioretinopathy
mild LD c.1039_1040delCT 9 p.Leu347Glufs*8
MLCRD06 I-1 male 4.3 congenital, bilateral,
and lower limb
none low birth weight,
failure
to thrive,
c.432T>G 5 p.Phe144Leu
MLCRD07 I-1c male 2.3 congenital, bilateral,
and lower limb
bilateral
chorioretinopathy
mild LD, ASD, and
myoclonic epilepsy
c.2830C>T (de novo) 20 p.Arg944Cys
MLCRD08 I-1 male 3.5 none none none c.1425_1426delinsAAA 12 p.Val476Asnfs*2
II-1 male 5.5 congenital, mild,
bilateral,
and lower limb
myopia moderate LD c.1425_1426delinsAAA 12 p.Val476Asnfs*2
MLCRD09 I-1 female 3.0 none none none c.1592delA 13 p.Gln531Argfs*8
II-1d male 4.0 congenital, bilateral,
and lower limb
bilateral
chorioretinopathy
ASD and dysmorphic
features
c.1592delA 13 p.Gln531Argfs*8
MLCRD10 I-1 male 5.5 congenital, mild,
bilateral, and mild lower
limb (resolved)
bilateral
chorioretinopathy
mild LD c.699-2A>G (de novo) 6/7 acceptor splice site
MLCRD11 II-1 male low by history congenital, bilateral,
and lower limb
plus mild in hands
none none c.2547þ2T>C 18/19 donor splice site
III-2 female 4.7 none none mild LD c.2547þ2T>C 18/19 donor splice site
IV-1 male 4.0 congenital, bilateral,
and lower limb plus
mild in hands
none moderate LD and
hypospadias
c.2547þ2T>C 18/19 donor splice site
IV-3 male 3.7 congenital, mild,
bilateral,
and lower limb
none moderate LD c.2547þ2T>C 18/19 donor splice site
IV-5 female 4.1 none none mild LD c.2547þ2T>C 18/19 donor splice site
3
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Table 1. Continued
Pedigree Individual Gender
Head
Circumferenceb Lymphedema Eye Abnormalities
Additional Clinical
Features Nucleotide Variant Exon Protein Alteration
MLCRD12 I-1 male 6.4 congenital, mild,
bilateral, and
lower limb
bilateral
chorioretinopathy
moderate LD c.1963_1964dupAA 15 p.His656Serfs*8
CDMMR01 II-1 female 5.0 adult onset and
post-traumatic
mild edema
chorioretinopathy mild LD c.1159C>T (de novo) 10 p.Arg387*
III-1 male 5.5 none hypermetropic
astigmatism and
chorioretinopathy
moderate LD c.1159C>T 10 p.Arg387*
CDMMR02 I-1 female low by history none bilateral
chorioretinopathy
none c.704C>G 7 p.Ser235Cys
II-1 female low by history none bilateral
chorioretinopathy
moderate LD c.704C>G 7 p.Ser235Cys
CDMMR03 I-1 male 3.4 none no vision in right
eye (retinal
detachment) and
peripheral retinal
atrophy in left eye
mild LD c.2304_2305delCA
(de novo)
18 p.His768Glnfs*7
CDMMR04 I-1 male 5.1 none chorioretinopathy,
nystagmus,
and exotropia
moderate LD c.700C>T 7 p.Arg234Cys
CDMMR05 II-1 female 3.9 none chorioretinopathy mild LD c.1804C>T 14 p.Gln602*
II-2 female 6.1 none hypermetropic
astigmatism
none c.1804C>T 14 p.Gln602*
Abbreviations are as follows: LD, learning difficulties; and ASD, atrial septal defect. Please see main text for additional abbreviations.
a Individuals exome sequenced in primary analysis.
b Head circumference measured as occipitofrontal head circumference in cm and corrected for age and sex.
c Case description in Vasudevan et al. (2005).4
d Case description in Eventon-Friedman et al. (2009).24
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Figure 2. Location of the Identified Mutations in KIF11
Upper panel: Mutations are indicated with respect to the genomic organization of KIF11.
Lower panel: KIF11 domain structure excludes the two identified splice-site mutations.Within the extended MLCRD-affected families, we
observed individuals who had heterozygous mutations in
KIF11 and in whom there was no evidence of lymphatic
involvement (Table 1). The considerable and recognizable
overlap between the two conditions led us to address the
hypothesis that MLCRD and CDMMR are allelic disorders.
Sequencing of KIF11 in a cohort of six independent fami-
lies in which microcephaly and eye abnormalities had
been observed in the absence of lymphedema revealed
five independent variants: Two missense substitutions
and three variants, including one nonsense mutation
(p.Arg387*) that we had previously identified in pedigree
MLCRD01, were predicted to lead to premature termina-
tion of the protein product (Table 1). In total, we identified
27 carriers of 14 mutant KIF11 alleles in 15 independent
families. None of the 14 variants is present in dbSNP, has
been identified by the 1000 Genomes Project, or was
observed in a cohort of 250 control samples.
We failed to identify coding variation in KIF11 in five
families from which four probands had previously been
diagnosed with MLCRD and one with CDMMR (Table
S1). These cases might represent KIF11 alleles comprising
noncoding or undetected coding variants. They might
represent phenocopies of MLCRD and CDMMR or be
explained by locus heterogeneity.We were unable to inves-
tigate the latter because none of the KIF11-mutation-nega-
tive families were of sufficient size to allow exclusion of the
locus by linkage analysis.
KIF11 encodes EG5, a bipolar, homotetrameric, slow-
processive, plus-end-directed spindle motor protein of
the kinesin-5 family.14 Each monomer contains a con-
served N-terminal motor, a central coiled-coil domain,
and aC-terminal tail that contains a bimC box, a conserved
sequence of positively charged amino acid residues
(Figure 2).15,16 The homotetramer consists of four mono-
mers that are arranged in an antiparallel fashion so that
the resulting molecule possesses two motor domains and
two nonmotor tails at each end of a central stalk. The360 The American Journal of Human Genetics 90, 356–362, Februarycontact of EG5 with microtubules is established through
the C-terminal tails, whereas the subsequent sliding of
the antiparallel microtubules is driven by the motor
domains.17 Seven of the identified allelic mutations, two
nonsense and five frameshift, including insertions and
deletions, are predicted to lead to premature termination
of the protein. A sixth frameshift variant, a single-base
deletion in the second-to-last exon, is predicted to result
in substitution of the terminal 50 residues of the 1,056
amino acid wild-type protein and extension of the reading
frame by a further 12 residues. The two splice-site muta-
tions are both predicted in HSF (Human Splicing Finder
v.2.4.1)18 to have significant impact on the splicing of
the 5 kb transcript (Table S6). The four missense mutations
all alter evolutionarily conserved amino acid residues and
are predicted to have a damaging effect on protein func-
tion according to SIFT and PolyPhen; three (p.Phe144Leu,
p.Arg234Cys, and p.Ser235Cys) are located within the
motor domain,15 and the fourth (p.Arg944Cys) is located
within the bimC box in the C-terminal tail of the molecule
(Figure S2).16
Kif11 has been shown to be widely expressed during
murine embryonic development and is elevated in prolif-
erating tissues.19,20 During zebrafish development, kif11
is dynamically expressed in tissues that are associated
with rapid proliferation (Figure S3). Interestingly, homozy-
gous disruption of Kif11 leads to early embryonic lethality,
and signs of a proliferation defect are shown at embryonic
day 2.5.19,20 It has been previously demonstrated that
EG5 localizes to spindle microtubules during mitosis
and also contributes to the assembly of the bipolar
spindle,21 as well as the regulation of axonal outgrowth22
and CNS development.23 Several genes (CENPJ, MCPH1,
ASPM, CDK5RAP2, STIL, CEP152, and WDR62 [MIM
608393, 251200, 608716, 604804, 612703, 604321, and
604317, respectively]) mutated in recessively inherited
microcephaly have products with roles in centrosome
formation and spindle development. Our identification10, 2012
of heterozygous KIF11 mutations in dominant forms of
microcephaly provides further evidence of the critical
role of molecules involved in mitotic spindle function in
CNS development. The observation of lymphedema and
chorioretinopathy provides evidence of a role of EG5 in
the development and maintenance of the lymphatic and
retinal structures. It is currently unclear whether MLCRD
and CDMMR result from disruption of the mitotic func-
tion of EG5 or from other roles of EG5 in the cell. The
recently defined function of EG5 as a brake onmicrotubule
activity as part of axonal turning22 provides the basis for
speculating that the dominant mutations observed in
this study might disrupt the control of lymphatic develop-
ment in a similar manner.
Our findings demonstrate a pleiotropic phenotypic
expression of mutant KIF11 alleles and show that MLCRD
and CDMMR are allelic disorders. Beyond the observed
variability of lymphatic and eye involvement, there is
also a range in the severity of microcephaly. Microcephaly
was primary (congenital) in all subjects, and there was
some correlation between the degree of microcephaly
and the severity of the learning disorder. Although all
probands were chosen because they had microcephaly,
there was marked intrafamilial variation (Table 1); one
parent had a normal head circumference, mild learning
difficulties, no lymphedema, and only a retinopathy asso-
ciated with her diabetes (MLCRD02 I-1).
Chorioretinopathy was a highly specific finding in
patients with KIF11 mutations, but none of the patients
had retinal folds or microphthalmia to suggest that the
condition originally described by Jarmas et al.5 might be
nonallelic. A number of patients with additional abnor-
malities (e.g., thrombocytopenia and craniosynostosis)
were not found to have KIF11 mutations. It could be rele-
vant for clinical differentiation that chorioretinopathy
was not observed in any of the KIF11-mutation-negative
subjects (Table S1), although numbers are too small for
this to be a definitive observation.
The lymphedema in the mutation-positive subjects was
present at birth and was restricted to both lower limbs
and rarely extended above the knees. The dorsa of the feet
were particularly affected and had small, dysplastic nails
and deep interphalangeal creases. There were often large-
caliber veins in the lower limbs. Clinically, the findings
resemble those seen inMilroy disease (Figure 1D). The lym-
phedema was usually persistent but responded well to
compression garments. Interestingly, there appeared to be
some intrafamilial consistency among the clinical features
regardless of the type of mutation, but such consistency is
difficult to verify with such small numbers.
In conclusion, we have identified KIF11 mutations that
cause autosomal-dominant forms of microcephaly that
are variably associated with congenital lymphedema and/
or chorioretinopathy, demonstrating that MLCRD and
CDMMR are allelic disorders. The extreme variability of
the phenotype, even between individuals with the same
KIF11 mutation, suggests that there might be additionalThe Americagenetic or environmental factors that contribute to the
extent of disruption. In addition, our findings also provide
a substantial foundation for the existence of a link between
EG5 and the development and maintenance of retinal and
lymphatic structures. It remains to be elucidated how far
the established mitotic function of EG5 can account for
the different phenotypical aspects ofMLCRD and CDMMR
and whether at least some defects are consequences of
a different role of EG5 during development.Supplemental Data
Supplemental Data include three figures and six tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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